Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17908830 | 1.00 | LMNA (0.52) | LMNAEPHX2ALDH1A1GAAPDE3B | |
| SCHEMBL26199851 | 0.89 | LMNA (0.46) | LMNAEPHX2ALDH1A1GAAMAPT | |
| SCHEMBL17909423 | 0.85 | LMNA (0.56) | LMNAEPHX2ALDH1A1GAAPDE3B | |
| SCHEMBL17908822 | 0.85 | LMNA (0.52) | LMNAEPHX2ALDH1A1GAAPDE3B | |
| SCHEMBL17908741 | 0.85 | LMNA (0.56) | LMNAEPHX2ALDH1A1GAAPDE3B | |
| SCHEMBL17909398 | 0.85 | LMNA (0.52) | LMNAEPHX2ALDH1A1GAAPDE3B | |
| SCHEMBL17909643 | 0.85 | LMNA (0.56) | LMNAEPHX2ALDH1A1GAAPDE3B | |
| SCHEMBL17909571 | 0.85 | LMNA (0.67) | LMNAALDH1A1MAPTHTTHSD17B10 | |
| SCHEMBL17909467 | 0.85 | LMNA (0.67) | LMNAALDH1A1MAPTHTTHSD17B10 | |
| SCHEMBL17909422 | 0.85 | LMNA (0.67) | LMNAALDH1A1MAPTHTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3048093-B1 | ETHER-CONTAINING MONOESTER COMPOUND AND USE THEREOF | MORESCO CORP (JP) | 2019-02-20 | — | — | EP | disclosed |
| US-10077229-B2 | Ether-containing monoester compound and use thereof | MORESCO CORPORATION (JP) | 2018-09-18 | — | — | US | disclosed |
| EP-3048093-A1 | ETHER-CONTAINING MONOESTER COMPOUND AND USE THEREOF | Moresco Corporation (JP) | 2016-07-27 | — | — | EP | disclosed |
| US-20160200998-A1 | ETHER-CONTAINING MONOESTER COMPOUND AND USE THEREOF | MORESCO CORPORATION (JP) | 2016-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077229-B2 | Ether-containing monoester compound and use thereof | SFN, CCNE2, HSD3B2 | LMNA 3897/4885EPHX2 200/4885ALDH1A1 1635/4885 |
| US-20160200998-A1 | ETHER-CONTAINING MONOESTER COMPOUND AND USE THEREOF | SFN, CCNE2, MSMO1 | LMNA 3960/4885EPHX2 182/4885ALDH1A1 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.